Trailing-twelve-month (TTM) revenue is $6.93 Million with a year-over-year growth of +11.42%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $2,011,556 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $1,016,698 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $1,654,227 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $2,246,909 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $6,929,390 |
Current P/S: $11,896,738 market capitalization ÷ $6,929,390 TTM revenue = 1.72x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:44:48.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.25M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:49:40.253Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20162016-12-31 · USD | FY20172017-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|---|
| International | N/A | N/A | N/A | N/A | -$847,000 | N/A |
| International Member | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|
| International | $1M | $411,000 |
| United States | $6M | -$27,000 |
$6.93M
$6.93 Million
+11.42%
vs. $6.22M a year ago (TTM)
(9.61%)
5 Year compound annual growth rate
1 Year
+11.42%
3 Year
(8.10%)
5 Year
(9.61%)
10 Year
+1.10%
15 Year
+25.61%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.64M | ($2.10M) | (27.17%) |
| 2024 | $7.74M | +$384,278 | +5.23% |
| 2023 | $7.35M | ($983,535) | (11.80%) |
| 2022 | $8.34M | +$584,517 | +7.54% |
| 2021 | $7.75M | ($17.27M) | (69.02%) |
| 2020 |
TTM Growth
+11.42%
3-Year CAGR
(8.10%)
5-Year CAGR
(9.61%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T19:49:40.253Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $726,000 |
| N/A |
| N/A |
| Product and Service Revenue | N/A | N/A | N/A | N/A | N/A | $8M |
|---|
| Product And Service Revenue | N/A | N/A | $8M | N/A | N/A | N/A |
|---|
| Revenue By Geographic Region | N/A | N/A | $8M | N/A | N/A | N/A |
|---|
| Service & Training | $616,000 | $893,000 | N/A | N/A | N/A | N/A |
|---|
| Service And Training | N/A | N/A | N/A | N/A | $186,000 | $130,000 |
|---|
| SteraMist Product | $6M | $4M | N/A | N/A | N/A | N/A |
|---|
| SteraMist PRoduct | N/A | N/A | N/A | N/A | -$1M | $254,000 |
|---|
| United States | N/A | N/A | N/A | N/A | -$136,000 | N/A |
|---|
| United States Member | N/A | N/A | N/A | -$142,000 | N/A | N/A |
|---|
| $25.03M |
| +$18.68M |
| +294.31% |
| 2019 | $6.35M | +$762,548 | +13.65% |
| 2018 | $5.58M | +$590,944 | +11.83% |
| 2017 | $4.99M | ($1.35M) | (21.28%) |
| 2016 | $6.34M | +$2.15M | +51.33% |
